Answer
Anti-VEGF eye medicines have a theoretical risk of arterial blood clots, and safety data are limited after a recent heart attack, stroke or transient ischaemic attack. The specialist must assess this before treatment.
Sources for this answer
- Lytenava 25 mg/mL solution for injection — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.